Jack A. Khattar's most recent trade in Supernus Pharmaceuticals Inc was a trade of 81,250 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Oct. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2025 | 81,250 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 09 Oct 2025 | 81,250 | 1,266,478 (2%) | 0% | 25.3 | 2,055,625 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 50.55 per share. | 09 Oct 2025 | 58,371 | 1,208,107 (2%) | 0% | 50.5 | 2,950,654 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 51.46 per share. | 09 Oct 2025 | 1,529 | 1,206,578 (2%) | 0% | 51.5 | 78,682 | Common Stock |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Oct 2025 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Oct 2025 | 19,750 | 0 | - | - | Stock Option (Right to Buy) | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Oct 2025 | 16,300 | 0 | - | - | Stock Option (Right to Buy) | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Oct 2025 | 6,124 | 0 | - | - | Stock Option (Right to Buy) | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | 07 Oct 2025 | 5,000 | 0 (0%) | 0% | - | Common Stock | ||
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 20,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 20,000 | 1,181,233 (2%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 19,320 | 0 | - | - | Performance Share Units | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 19,320 | 1,192,757 (2%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.21 per share. | 02 Oct 2025 | 7,796 | 1,173,437 (2%) | 0% | 46.2 | 360,253 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.21 per share. | 02 Oct 2025 | 7,529 | 1,185,228 (2%) | 0% | 46.2 | 347,915 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 02 Oct 2025 | 2,267 | 1,163,137 (2%) | 0% | 25.3 | 57,355 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 2,267 | 81,250 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 48.06 per share. | 02 Oct 2025 | 1,904 | 1,161,233 (2%) | 0% | 48.1 | 91,506 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 01 Oct 2025 | 53,785 | 1,201,043 (2%) | 0% | 25.3 | 1,360,761 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 53,785 | 83,517 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 48.07 per share. | 01 Oct 2025 | 40,173 | 1,160,870 (2%) | 0% | 48.1 | 1,931,116 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 30 Sep 2025 | 11,510 | 1,155,846 (2%) | 0% | 25.3 | 291,203 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2025 | 11,510 | 137,302 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 48.25 per share. | 30 Sep 2025 | 8,588 | 1,147,258 (2%) | 0% | 48.3 | 414,371 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2025 | 13,688 | 148,812 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 29 Sep 2025 | 13,688 | 1,154,571 (2%) | 0% | 25.3 | 346,306 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 48.02 per share. | 29 Sep 2025 | 10,235 | 1,144,336 (2%) | 0% | 48.0 | 491,485 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 23 Sep 2025 | 47,940 | 1,170,396 (2%) | 0% | 13.0 | 622,261 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2025 | 47,940 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 47.23 per share. | 23 Sep 2025 | 29,513 | 1,140,883 (2%) | 0% | 47.2 | 1,393,899 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 22 Sep 2025 | 27,060 | 1,139,043 (2%) | 0% | 13.0 | 351,239 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Sep 2025 | 27,060 | 47,940 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 47.02 per share. | 22 Sep 2025 | 16,587 | 1,122,456 (2%) | 0% | 47.0 | 779,921 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2025 | 20,000 | 20,000 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2025 | 19,320 | 19,320 | - | - | Performance Share Units | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2025 | 8,074 | 162,500 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 08 Sep 2025 | 8,074 | 1,118,305 (2%) | 0% | 25.3 | 204,272 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 46.29 per share. | 08 Sep 2025 | 6,322 | 1,111,983 (2%) | 0% | 46.3 | 292,645 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 05 Sep 2025 | 73,176 | 1,165,809 (2%) | 0% | 25.3 | 1,851,353 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2025 | 73,176 | 170,574 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 46.01 per share. | 05 Sep 2025 | 55,578 | 1,110,231 (2%) | 0% | 46.0 | 2,557,144 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 27 Aug 2025 | 38,779 | 1,116,783 (2%) | 0% | 13.0 | 503,351 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 38,779 | 75,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.12 per share. | 27 Aug 2025 | 24,150 | 1,092,633 (2%) | 0% | 45.1 | 1,089,648 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2025 | 17,195 | 113,779 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 27 Aug 2025 | 17,195 | 1,088,654 (2%) | 0% | 13.0 | 223,191 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.05 per share. | 27 Aug 2025 | 10,650 | 1,078,004 (2%) | 0% | 45.1 | 479,783 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 25 Aug 2025 | 1,611 | 1,072,459 (2%) | 0% | 13.0 | 20,911 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2025 | 1,611 | 130,974 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 25 Aug 2025 | 1,000 | 1,071,459 (2%) | 0% | 45 | 45,000 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 22 Aug 2025 | 2,415 | 1,072,348 (2%) | 0% | 13.0 | 31,347 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2025 | 2,415 | 132,585 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 22 Aug 2025 | 1,500 | 1,070,848 (2%) | 0% | 45 | 67,500 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.30 per share. | 06 Aug 2025 | 81,250 | 1,133,433 (2%) | 0% | 25.3 | 2,055,625 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2025 | 81,250 | 243,750 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 43.12 per share. | 06 Aug 2025 | 63,500 | 1,069,933 (2%) | 0% | 43.1 | 2,738,120 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2025 | 60,000 | 135,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2025 | 60,000 | 195,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 06 Aug 2025 | 60,000 | 1,090,183 (2%) | 0% | 13.0 | 778,800 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 06 Aug 2025 | 60,000 | 1,068,683 (2%) | 0% | 13.0 | 778,800 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 40.24 per share. | 06 Aug 2025 | 38,500 | 1,030,183 (1%) | 0% | 40.2 | 1,549,240 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 06 Aug 2025 | 38,000 | 1,052,183 (2%) | 0% | 42 | 1,596,000 | Common Stock |
| Cognition Therapeutics Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 34,000 | 48,500 | - | 0 | Common Stock | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 02 Apr 2025 | 16,850 | 1,008,683 (1%) | 0% | - | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Other type of transaction at price $ 0.00 per share. | 02 Apr 2025 | 16,850 | 1,005,600 (1%) | 0% | - | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 35,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 35,000 | 1,008,638 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.06 per share. | 10 Mar 2025 | 16,805 | 991,833 (1%) | 0% | 32.1 | 538,768 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 38,640 | 0 | - | - | Performance Share Units | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 38,640 | 992,219 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.11 per share. | 07 Mar 2025 | 18,581 | 973,638 (1%) | 0% | 39.1 | 726,703 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 35,000 | 35,000 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 331,660 | 331,660 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2025 | 38,640 | 38,640 | - | - | Performance Share Units | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 38,640 | 964,812 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Khattar Jack A. | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 38,640 | 0 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Khattar A. Jack | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.59 per share. | 27 Dec 2024 | 18,567 | 946,245 (1%) | 0% | 35.6 | 660,800 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 14,000 | 960,245 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Khattar Jack A. | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 14,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.59 per share. | 27 Dec 2024 | 6,666 | 953,579 (1%) | 0% | 35.6 | 237,243 | Common Stock |
| Supernus Pharma Inc | A. Jack Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 38,640 | 38,640 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 14,000 | 14,000 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.13 per share. | 08 Nov 2024 | 125,000 | 1,051,172 (2%) | 0% | 9.1 | 1,141,250 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 36.29 per share. | 08 Nov 2024 | 125,000 | 926,172 (1%) | 0% | 36.3 | 4,536,250 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 125,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 36.68 per share. | 07 Nov 2024 | 125,000 | 926,172 (1%) | 0% | 36.7 | 4,585,000 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.13 per share. | 07 Nov 2024 | 125,000 | 1,051,172 (2%) | 0% | 9.1 | 1,141,250 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 21,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 21,000 | 936,217 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.90 per share. | 03 Sep 2024 | 10,045 | 926,172 (1%) | 0% | 34.9 | 350,571 | Common Stock |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2024 | 21,000 | 21,000 | - | - | Performance Share Unit | |
| scPharmaceuticals Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 19,750 | 19,750 | - | - | Stock Option (Right to Buy) | |
| Cognition Therapeutics Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 8,500 | 14,500 | - | 0 | Common Stock | |
| Cognition Therapeutics Inc | Jack A. Khattar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 8,500 | 8,500 | - | - | Stock Option (right to buy) | |
| Supernus Pharma Inc | Khattar Jack A. | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 35,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharma Inc | A. Jack Khattar | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 35,000 | 932,005 (1%) | 0% | 0 | Common Stock | |
| Supernus Pharma Inc | Jack A. Khattar | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 28 Feb 2024 | 16,788 | 915,217 (1%) | 0% | 27.9 | 469,057 | Common Stock |
| Supernus Pharma Inc | Jack Khattar A. | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 322,000 | 322,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharma Inc | A. Khattar Jack | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 35,000 | 35,000 | - | - | Performance Share Unit |